B&K Corporation (HKG:2396) said it enrolled the first patient in the phase 3a clinical trial of Pro-101-1 to treat deep second-degree burns, according to a Tuesday filing with the Hong Kong bourse.
The biopharmaceutical company shares fell 1% in morning trade Wednesday.
Pro-101-1 is one of the core products of the company.